Sponsors

Lead Sponsor

Assuntina G. Sacco, MD

Collaborators

The V Foundation for Cancer Research

This is a phase 2 window of opportunity trial in patients with locally advanced head and neck cancer. A key objective is to provide the first proof that macrophage phenotype switching can be accomplished in humans and lay the groundwork for future trials of this novel approach to immune therapy. Patients who are candidates for surgical resection will be enrolled and treated with 2 weeks of IPI-549, a specific PI3Kγ inhibitor. Tumor tissue for research purposes through core biopsies will be obtained prior to initiation of IPI-549 and at surgery. The study team hypothesizes that mRNA signatures of immune response will be increased in IPI-549-treated patients. For the efficacy endpoints, RECISTv1.1 will be used.

Related studies

RECRUITINGPhase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

NCT06980038 · Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, and more

RECRUITINGPhase 2

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

NCT07040956 · Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, and more

RECRUITING

DESTINY-PANTUMOUR04

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

RECRUITINGNA

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

NCT04541381 · Gastrointestinal Cancer, Head and Neck Cancer, and more

RECRUITINGPhase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more

View all related studies →

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

DESTINY-PANTUMOUR04

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Trial snapshot

Condition

Locations shown

For caregivers